Guerbet and Intrasense announce CE marking of DUOnco™ Liver, an artificial intelligence algorithm designed for the detection of focal liver lesions – 09/23/2024 at 5:45 p.m.

Montpellier, France, September 23, 2024 at 5:45 p.m. CEST

Guerbet (FR0000032526 GBT), a global leader in medical imaging, and Intrasense (FR0011179886 – ALINS), a specialist in medical imaging software solutions and designer of Myrian® and Liflow®, announce the CE marking under MDR of the liver AI developed by Guerbet (trade name: DUOnco™ Liver).

“Obtaining certification for our DUOnco™ Liver AI marks a significant step forward in our innovation strategy. We developed this algorithm with the conviction that it could be a real game-changer in helping to detect and monitor liver metastases,” says François Nicolas, Director of Research, Development, Innovation and AI at the Guerbet group.

Alexandre Salvador, CEO of Intrasense, said: “We are extremely proud to see the liver algorithm, developed by Guerbet, receive the CE marking under MDR and enrich our Liflow® 2.0 solution. This recognition validates not only the technological excellence of our solutions, but also our commitment to offering healthcare professionals cutting-edge tools. In five months, this is the second Guerbet AI that we have transferred, demonstrating a great synergy in our technical collaboration. This is a decisive step in our mission to help make diagnostics more accurate, faster and more accessible.”